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Abstract
Purpose Vascular stiffness may potentially be used as a
s c r e e n i n gt o o lt oi d e n t i f ya s y m p t o m a t i cp a t i e n t sw i t h
diabetes with abnormal myocardial perfusion. The purpose
of this study was therefore to determine the association
between vascular stiffness, measured in term of pulse wave
velocity (PWV) and augmentation index (AIx), and
abnormal myocardial perfusion imaging (MPI) in asymp-
tomatic patients with diabetes.
Methods Prospectively, 160 asymptomatic patients with
diabetes (mean age 51 years, 87 men) underwent MPI with
adenosine stress. The summed stress score (SSS) was
determined in each patient according to a 17-segment and
five-point score. Abnormal MPI (SSS ≥3) was classified as
moderate (SSS 3–7) or severe (SSS ≥8) MPI defects. Using
applanation tonometry, the carotid–femoral PWV and the
radial AIx corrected to 75 beats per minute were determined
noninvasively.
Results MPI was abnormal in 61 patients (38%), with severe
MPI defects in 22 patients (14%). Mean PWV increased with
deteriorating MPI from 8.4±2.2 m/s in normal MPI to 9.0±
2.2m/sinmoderateMPIdefects(p=0 . 1 1 )a n dt o1 1 . 1±2 . 5m / s
in severe MPI defects (p<0.01). Likewise, mean AIx
increased from 18.4±13.4% to 19.4±10.7% (p=0.66) and to
25.4±9.0% (p=0.03). After adjustment for age and other risk
factors, PWV remained a significant predictor of severe MPI
defects (p=0.01, OR 1.50, 95% CI 1.11–2.00), whereas AIx
was no longer significant (p=0.20).
Conclusion Vascular stiffness measured by PWV is associ-
ated with severe MPI defects in asymptomatic patients with
diabetes.
Keywords Diabetes mellitus.Vascular stiffness.
Myocardial perfusion imaging.Coronary artery disease
Introduction
It is considered that the global prevalence of diabetes will
approximately double in the next two decades [1]. Diabetes
is associated with a marked increase in the incidence of
cardiovascular morbidity and mortality, mainly attributable
to coronary artery disease (CAD). Moreover, the presence
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asymptomatic, leading to more extensive disease at the
time of diagnosis [2]. Since a delayed diagnosis of CAD
considerably worsens the prognosis, early recognition of
CAD could lead to more effectively targeted intervention
and reduce morbidity and mortality in this population.
Myocardial perfusion imaging (MPI) with SPECT is most
commonly used to identify patients with CAD, and can
accurately identify patients at increased cardiovascular risk
[2–4]. However, based on recent data, a wide ranging
routine MPI screening strategy of all asymptomatic patients
with diabetes would appear to be ineffective [5]. Accord-
ingly, a selective “prescreening” strategy using an initial test
for the identification of patients with a higher likelihood of
abnormal MPI followed by referral of only these patients to
MPI may be preferred. Noninvasive assessment of vascular
stiffness could represent a promising tool for this purpose.
In several studies, a relationship between vascular stiffness
and cardiovascular disease has been observed [6–8].
Assessment of vascular stiffness by means of pulse wave
velocity (PWV) or pulse wave analysis for augmentation
index (AIx) may therefore have the potential to serve as a
marker of abnormal MPI. Although PWV and AIx have
been extensively studied in the general population [9–13],
fewer data are available concerning their relationship with
CAD in asymptomatic patients with diabetes.
The aim of the current study was to prospectively assess
the relationship between the noninvasive measures of
vascular stiffness (PWV and AIx) with the presence and
extent of myocardial perfusion defects as assessed by
SPECT MPI in asymptomatic patients with diabetes.
Methods
Study population
Prospectively, 160 consecutive asymptomatic patients with
diabetes were recruited from a routine outpatient clinic.
Patients were referred to the cardiology outpatient clinic for
risk assessment and cardiovascular screening. Anginal
symptoms were ruled out using a self-completed question-
naire for encountered chest pain [14]. The American
Diabetes association (ADA) criteria were used to identify
diabetes and for further stratification into type 1 or 2
diabetes [15]. Patients were considered as having type 1
diabetes if laboratory analysis demonstrated autoantibodies
to islet cells, insulin and glutamic acid decarboxylase or
low levels of plasma c-peptide. Otherwise, patients were
considered to have type 2 diabetes. Medical history and
demographics were obtained. All patients underwent
physical examination, and blood and urine laboratory
testing. MPI was performed as part of the clinical work-up
to determine the presence and extent of myocardial perfusion
defects. Additionalmeasurements of PWVand AIx were used
to assess vascular stiffness.
Cardiovascular risk factors
Cardiovascular risk factors were defined according to the
following criteria: positive family history for CAD (pres-
ence of CAD in first-degree family members, male <55
years and/or female <65 years), smoking (current smoking
or smoking in the last 2 years), hypertension (blood
pressure >140/90 mmHg or treatment with antihypertensive
medication), body mass index, hypercholesterolaemia (total
cholesterol level >5.0 mmol/l or use of cholesterol-lowering
medication), and microalbuminuria (urine albumin/creatinine
ratio ≥3.5 mg/mmol) [2]. Plasma haemoglobin A1c (HbA1c)
was determined as a measure of glycaemic control.
SPECT myocardial perfusion imaging
SPECT data acquisition
ECG-gated adenosine
99mTc sestamibi (
99mTc MIBI)
SPECT MPI was performed using a 2-day protocol,
comprising stress imaging on the first day and a rest scan
on the second day [16]. Antihypertensive treatment with
beta-adrenergic blocking agents or calcium antagonists was
stopped and patients were instructed to abstain from
caffeine-containing products 24 h prior to the stress test.
Vasodilator stress was induced by intravenous infusion of
adenosine 140 μg/kg per minute for 6 min, with a
simultaneous hand-grip exercise.
99mTc MIBI (500 MBq)
was injected intravenously after the third minute. Blood
pressure and a 12-lead ECG were recorded throughout the
adenosine infusion.
I m a g e sw e r ea c q u i r e d2ha f t e ri n j e c t i o no ft h e
radiopharmaceutical using a triple-head SPECT gamma
camera (GCA 9300/HG; Toshiba, Tokyo, Japan) with low-
energy, high-resolution collimators. Images were acquired
using a circular 360° orbit, 60 projections and 40 s per
projection, in compliance with the American Society of
Nuclear Cardiology (ASNC) imaging guidelines. Images
were processed to obtain the short-axis, vertical long-axis
and horizontal long-axis sections, as well as polar map
formats, normalized to maximal myocardial activity [16].
Patient motion was reviewed by examining the raw cine
images. No attenuation or scatter correction was used.
SPECT data analysis
For semiquantitative visual interpretation, the myocardium
was divided into 17 segments according to ASNC guide-
lines [16]. Tracer uptake in each segment was evaluated in
Eur J Nucl Med Mol Imaging (2011) 38:2050–2057 2051consensus by two expert observers blinded to the patient’s
clinical characteristics and test results using a five-point
scoring system ranging from 0 (normal uptake) to 4 (absent
uptake). The summed stress score (SSS) was determined as
the sum of the 17 segmental scores of the stress images.
MPI was considered normal for SSS <3. In case of
abnormal MPI, SSS in the range 3–7 were considered to
represent moderate MPI defects, and SSS ≥8 to represent
severe MPI defects [17]. Finally, regional wall motion on
gated SPECT images was evaluated to allow differentiation
between true MPI abnormalities and diaphragmatic or
breast attenuation artifacts.
Assessment of vascular stiffness
Measurements were derived and analysed noninvasively by
applanation tonometry using a SphygmoCor system (Atcor
Medical, Sydney, Australia). All measurements were per-
formed in the morning in a quiet, temperature-controlled
clinical research laboratory by a specially trained technologist
blinded to the patient’s clinical characteristics and test results.
The patients were instructed to omit their morning medication
and continue fasting until after the test. Assessment of PWV
and pulse wave analysis commenced following a 10-min rest
in a supine position after a state of constant heart rate and
blood pressure had been reached.
Pulse wave velocity
The pulse waves were recorded at the common carotid artery
and the femoral artery by sequential tonometry with simulta-
neous electrocardiographic gating. Pulse transit time was
determined as the average of ten consecutive beats. The
distance between the two sites was measured. Aortic PWV
(m/s) was defined as the distance between the two recording
sites travelled by the pulse wave divided by the transit time.
Using system software, aortic PWV was determined semiau-
tomatically. The validation and reproducibility of this semi-
automatic method have been previously published [18].
Measurements were performed three times in each patient
and averaged to obtain the mean aortic PWV.
Pulse wave analysis
The peripheral pressure waveforms were recorded from the
radial artery at the wrist with a hand-held high-fidelity
tonometer (Millar Instruments, Houston, TX) and calibrated
by peripheral blood pressures at the brachial artery [7, 19].
The corresponding central aortic pressure waveform was
generated by a validated generalized transfer function. The
central aortic pressure waveform was analysed to identify
the first shoulder of the pressure wave representing the
incident wave attributable to left ventricular ejection. The
merging point of the incident and the reflected wave (the
inflection point) was then identified on the generated aortic
pressure waveform. The absolute augmented pressure was
the maximum systolic pressure minus the pressure at the
inflection point. Subsequently, the AIx was defined as the
absolute augmented pressure divided by the pulse pressure
and expressed as a percentage [7, 8]. Finally, the AIx was
normalized to a heart rate of 75 bpm (AIx@75). In each
patient, three consecutive waveform recordings were
averaged to obtain the mean AIx@75, which was used for
statistical analysis.
Statistical analysis
Continuous variables are expressed as means±standard
deviation and categorical variables as numbers (percen-
tages). Firstly, associations of PWV and AIx@75 with
baseline clinical risk factors were assessed using Pearson’s
correlation coefficient (r) or Spearman’s rank correlation
coefficient (rs) in case of dichotomous variables. Secondly,
differences in the mean PWV and AIx@75 for each group
of MPI results were evaluated with the independent t-test.
Thereafter, with univariate logistic regression analysis
potential predictors of severe MPI defects were identified.
Subsequently, all potential predictors were analysed in a
multivariate logistic regression model to identify the
independent predictors of severe MPI defects. Additionally,
patients were categorized according to PWV quartiles and
for each quartile the prevalence of severe MPI defects was
obtained. Subsequently, a global chi-squared analysis was
used to determine the incremental predictive value of PWV
over baseline characteristics. Thereafter, using receiver
operating characteristic (ROC) curve analysis two cut-off
values were chosen for PWV, one for the detection of severe
MPI defects with optimal sensitivity and specificity and the
other for the exclusion of severe MPI defects with optimal
sensitivity and negative predictive value. All statistical
analyses were performed using SPSS software (version
16.0; SPSS, Chicago, IL). All p-values <0.05 were
considered statistically significant.
Results
Patient characteristics
The study population comprised 160 asymptomatic diabetic
patients. Their baseline characteristics are provided in Table 1.
SPECT myocardial perfusion imaging
The overall mean SSS was 3.1±4.1 (range 0–21). Abnormal
MPI (SSS ≥3) was observed in 60 patients (38%), including
2052 Eur J Nucl Med Mol Imaging (2011) 38:2050–2057moderate MPI defects (SSS 3–7) in 38 patients (24%) and
severe MPI defects (SSS ≥8) in 22 patients (14%).
Vascular stiffness
Pulse wave velocity
The overall mean PWV was 8.9±2.4 m/s. PWV was
associated with age (r=0.62, p<0.01), type 2 diabetes (rs=
0.23, p<0.01), diabetes duration (r=0.30, p<0.01), body
mass index (r=0.22, p<0.01), hypertension (rs=0.43, p<
0.01) and microalbuminuria (r=0.29, p<0.01). As shown
in Fig. 1a, mean PWV was only slightly lower in patients
with normal MPI than in patients with moderate MPI
defects (8.4±2.2 m/s and 9.0±2.2 m/s, respectively; p=0.11).
However, the mean PWV was significantly higher in patients
with severe MPI defects (11.1±2.5 m/s; p<0.01).
Association between pulse wave analysis and myocardial
perfusion
The mean AIx was 21.1±12.3% in the total population.
Normalization for a heart rate of 75 beats per minute
resulted in an overall mean AIx@75 of 19.6±12.4%. A
significant association was observed between AIx@75
and the following risk factors: age (r=0.47, p<0.01),
male gender (rs=-0.43, p<0.01), type 2 diabetes (rs=0.30,
p<0.01), hypercholesterolaemia (rs=0.17, p<0.03) and
microalbuminuria (r=0.26, p<0.01).
After stratification of the mean AIx@75 values according
to SPECT MPI results, a trend similar to that for PWV was
observed. Likewise, mean AIx@75 was slightly higher in
patients with moderate MPI defects than in those with normal
MPI (19.4±10.7% and 18.4±13.4%, respectively; p=0.66),
and was significantly higher in patients with severe MPI
defects (25.4±9.0%; p=0.03; Fig. 1b).
Predictors of severe myocardial perfusion defects
As illustrated in Table 2, age, gender, smoking, HbA1c,
microalbuminuria and both PWV and AIx@75 were
identified as potential predictors of severe MPI defects in
a univariate logistic regression model. Of note, after
adjustment for age, gender, smoking, HbA1c and micro-
albuminuria, the PWV remained a significant predictor of
severe MPI defects (p=0.01), whereas the AIx@75 was no
longer significant.
As demonstrated in Fig. 2, the prevalence of severe MPI
defects gradually increased with increasing PWV quartile.
Importantly, in none of the patients in the lowest PWV
Table 1 Baseline characteristics of the study population of 160
diabetic patients
Clinical factors Mean±SD or number (%)
Age (years) 51±12
Men 87 (54)
Type 2 diabetes 91 (57)
Diabetes duration (years) 15±13
Insulin use 125 (78)
Family history of CAD 75 (47)
Smoking 42 (26)
Body mass index (kg/m²) 28±6
Plasma haemoglobin A1c (mmol/l) 8.2±1.7
Hypertension 92 (58)
Use of antihypertensive medication 76 (48)
ACE-inhibitor use 43 (27)
Beta-blocker use 19 (12)
Systolic blood pressure (mmHg) 133±16
Diastolic blood pressure (mmHg) 80±9
Hypercholesterolaemia 107 (67)
Cholesterol-lowering medication 73 (46)
Total cholesterol (mmol/l) 4.8±1.1
Microalbuminuria 39 (24)
Aspirin use 31 (19)
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Fig. 1 Relationship between
parameters of vascular stiffness
and the extent of MPI defects
as assessed by SPECT MPI.
a Mean aortic PWV was higher
in patients with abnormal MPI.
The highest PWV was observed
in patients with severe MPI
defects. b The relationship
between mean AIx@75
and MPI shows a similar trend
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relatively small proportion of patients (5%) in the second
PWV quartile had severe MPI defects. In contrast, the
prevalence of severe MPI defects was 20% in the third
PWV quartile, and was 30% in the fourth quartile.
Moreover, the addition of PWV to a model with baseline
clinical risk factors age, gender and smoking for the
prediction of severe MPI defects showed a significantly
improved predictive value of PWV (Fig. 3).
ROCcurve analysisfor thedetectionofsevereMPI defects
showed the highest sensitivity and specificity (77% and 75%,
respectively)witha PWVcut-off value of9.8m/s.Anoptimal
sensitivity of 91% with an associated negative predictive
value of 98% for the exclusion of severe MPI defects was
found using a cut-off value of 9.2 m/s for PWV (Fig. 4).
Discussion
In the present study of asymptomatic patients with diabetes,
vascular stiffness as assessed by PWVand AIx was greater in
the presence of severe MPI defects. PWV was independently
associated with severe MPI defects, whereas AIx was no
longersignificant after correctionfor other cardiovascular risk
factors and PWV. Addition of PWV to a model of baseline
clinical risk factors showed significant incremental value for
thepredictionofsevereMPIdefects.Furthermore,ROCcurve
analysis revealed a moderate to good sensitivity of 77% and a
specificity of 75% for the detection of severe MPI defects,
withaPWVcut-offvalueof9.8m/s.Conversely,changingthe
cut-off value to 9.2 m/s resulted in a high sensitivity of 91%
and negative predictive value of 98% for the exclusion of
severe MPI defects. Accordingly, the current results indicate
that noninvasive evaluation of vascular stiffness may be a
practical tool for prescreening asymptomatic patients with
Clinical characteristic Exp β (95% CI) p-value Exp β (95% CI) p-value
Age 1.09 (1.04–1.14) <0.01 1.06 (0.98–1.14) 0.16
Male gender 3.30 (1.15–9.45) 0.03 6.35 (1.47–27.41) 0.01
Type 2 diabetes 1.47 (0.55–3.90) 0.44
Diabetes duration (years) 1.02 (0.99–1.06) 0.15
Family history of CAD 1.16 (0.47–2.85) 0.75
Smoking 3.80 (1.48–9.77) 0.01 5.74 (1.35–24.46) 0.02
Body mass index (kg/m²) 0.99 (0.91–1.07) 0.77
HbA1c (mmol/l) 1.28 (1.00–1.65) 0.05 1.52 (1.03–2.25) 0.03
Hypertension 1.98 (0.73–5.41) 0.18
Hypercholesterolaemia 1.65 (0.57–4.79) 0.36
Microalbuminuria 3.86 (1.52–9.81) 0.01 1.05 (0.26–4.27) 0.95
PWV 1.49 (1.22–1.81) <0.01 1.49 (1.11–2.00) 0.01
AIx@75 1.06 (1.01–1.11) 0.02 1.05 (0.97–1.14) 0.20
Table 2 Predictors of severe
MPI defects (SSS ≥8) on
SPECT
Fig. 2 Prevalence of patients with severe MPI defects per PWV
quartile. The prevalence of severe MPI defects increased with
increasing PWV. Of note, the prevalence of severe MPI defects chiefly
increased in the third and fourth PWV quartile
Fig. 3 Incremental predictive value of PWV for the detection severe
MPI defects as shown by an increase in the value of global chi-
squared. Addition of PWV to a model with baseline clinical risk
factors age, gender and smoking provided a significantly improved
predictive value
2054 Eur J Nucl Med Mol Imaging (2011) 38:2050–2057diabetes for differentiation into a higher and lower likelihood
of abnormal MPI.
Vascular stiffness and relationship to CAD
In the general population the relationship between vascular
stiffness and the presence of CAD has been confirmed in a
considerable number of studies. Vascular stiffness measured
as PWV or AIx not only is directly associated with the
presence and severity of CAD on invasive coronary
imaging [10], but also has incremental prognostic value
for predicting cardiovascular events [9, 11–13]. A recent
meta-analysis (15,877 subjects, 17 studies, average follow-
up of 7.7 years) has shown that the risk of cardiovascular
events is increased twofold in patients with increased PWV
[20]. Moreover, the predictive ability of PWV was shown to
be even higher in patients with elevated baseline cardio-
vascular risk, supporting a role for PWV in high-risk
populations such as patients with diabetes.
A few studies have specifically evaluated vascular
stiffness in patients with diabetes. Cruickshank et al.
evaluated the prognostic value of PWV for all-cause and
cardiovascular mortality in 397 patients with diabetes with
or without CAD. During a mean follow-up of 10.7 years,
aortic PWV was an independent predictor for all-cause and
cardiovascular mortality [21]. Additionally, Hatsuda et al.
found in 595 patients with diabetes that PWV was
significantly increased in 70 patients with established
CAD [22]. Finally, Fukui et al. investigated 208 consecu-
tive patients with type 2 diabetes and reported that AIx was
significantly higher in 47 patients with previously con-
firmed CAD [23]. These observations indicate that markers
of vascular stiffness may indeed be associated with CAD in
patients with diabetes.
However, to our knowledge this is the first study in
which PWV and AIx have been applied in asymptomatic
patients with diabetes to prospectively identify the presence
of CAD defined by the presence of (severe) MPI defects.
Although both PWV and AIx were higher in patients with
severe MPI defects, only PWV was shown to be an
independent predictor of severe MPI defects. These observa-
tions are in agreement with the previous literature as more
discrepant results have also been reported in the general
population using AIx as compared to PWV [24, 25].
Possibly, the more variable results with AIx may be
explained by underlying methodological differences. Carotid–
femoral PWV is a direct measure of vascular stiffness as
determined by the intrinsic stress/strain relationship of the
arterial wall and mean arterial pressure. Therefore PWV is
considered as the ‘gold-standard’ [6–8]. In contrast, AIx is an
indirect measurement derived from peripherally recorded
pressure waveforms. Using a generalized transfer function
the corresponding central arterial waveform is generated, from
which AIx is determined. Therefore, AIx is influenced by
multiple factors such as PWV, heart rate, diastolic blood
pressure, peripheral circulation and endothelial function [7, 8].
Furthermore, its discriminatory value may be less in the
elderly [24, 25], and the use of the generalized transfer
function may also be inappropriate in certain populations [24–
27]. In fact, Hope et al. recently evaluated the validity of this
method in patients with diabetes and found that estimation of
central pressures was prone to substantially greater error in
this population [26]. Similar differences in accuracy have also
been reported in relation to gender, indicating that AIx might
be a less representative marker of vascular stiffness than PWV
[24, 25]. Conceivably, the weaker association between AIx
and CAD as compared to PWV may therefore be explained
by the fact that our study was performed in patients with
diabetes while also including a high percentage of female
patients.
Clinical implications and perspectives
At present, screening of asymptomatic patients with
diabetes for CAD remains controversial. The majority of
available data are based on CAD detection using SPECT
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Fig. 4 Detection of severe MPI
defects on SPECT by PWV.
a ROC curve analysis for the
detection of severe MPI defects
yielded an optimal sensitivity
and specificity of 77% and 75%,
respectively, with a PWV cut-off
value of 9.8 m/s. b In contrast,
optimization for the exclusion of
severe MPI defects resulted in a
cut-off value of 9.2 m/s with a
sensitivity of 91% and a
corresponding negative
predictive value of 98%
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MPI was 38%. In contrast, the recent DIAD trial demon-
strated a much lower rate of abnormal MPI with only a few
patients having severe MPI defects [5, 28]. To a large
extent, this discrepancy may be explained by differences in
baseline characteristics of the enrolled patients. Importantly,
cardiac event rates were low in the DIAD study and not
significantly reduced by a MPI-based screening strategy.
Nevertheless, in the small group of patients with abnormal
MPI, a step-wise increase in event rates was observed with
increasing MPI abnormality. Of note, hard event rates were
2% in patients with normal scans but were 12% in patients
with at least moderately abnormal MPI scans. In contrast to
the general asymptomatic diabetic population, these high-
risk patients may benefit from screening, as also suggested
by the bypass angioplasty revascularization investigation
BARI 2 diabetes trial [29, 30]. In this trial no survival
benefit was shown in patients undergoing early coronary
revascularization as compared to intensive medical treat-
ment. However, among high-risk patients selected for
coronary artery bypass grafting, prompt revascularization
was associated with a lower rate of major cardiovascular
events than medical therapy. Accordingly, these observa-
tions indicate that while routine screening for abnormal
MPI may not be effective in asymptomatic patients with
diabetes, selective screening strategies are warranted to
identify the small but high-risk subgroup within this
population. In this regard, our current study may provide
valuable data for the design of such strategies. Assessment
of vascular stiffness by means of PWV was shown to
accurately identify patients with a high risk of severe MPI
defects. Accordingly, further screening in patients with
elevated PWV may be recommended. On the other hand,
when using a slightly lower cut-off value, PWV was also
shown to have a high negative predictive value, indicating
that PWV can accurately rule out severe MPI defects.
Therefore, further evaluation in patients with a negative
PWV study may be safely omitted.
Duetoitslowcostandnoninvasivenature,PWVmaybea
practical first-line tool to differentiate patients with a higher
and lower likelihood of having abnormal MPI. A number of
limitations must be acknowledged in the current study. Some
of the observed MPI defects may be attributed to artifact
attenuation. However, regional wall motion on gated SPECT
images was analysed for optimal differentiation between true
MPI defects and attenuation artifacts. Evidently, larger
prospective studies are needed to demonstrate the effective-
ness of this strategy in terms of cost and outcome.
Conclusion
Vascular stiffness as noninvasively assessed by PWV is
related to severely abnormal myocardial perfusion in
asymptomatic patients with diabetes. Accordingly, PWV
could be a practical tool to identify patients at higher risk of
CAD and who could benefit from further screening.
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